Radioimmunotherapy potential has also been shown for 99mTc and 188Re anti-CD20 (rituximab) in lymphoma, 99mTc and 188Re trastuzumab for breast cancer, 99mTc and 188Re bevacizumab in non–small cell lung cancer, 99mTc and 188Re cetuximab in lung cancer, 99mTc and 188Re anti-EGFR antibody h-R3 (nimotuzumab) in glioma, and 99mTc and 188Re anti-CEA MN-14 antibody in gastrointestinal cancers (86). Here, EGFR is linked to lung carcinoma.